Insulin edema in slowly progressive type 1 diabetes: improvement following adjustment of insulin therapy.

IF 1.2 Q4 ENDOCRINOLOGY & METABOLISM
Diabetology International Pub Date : 2025-12-29 eCollection Date: 2026-01-01 DOI:10.1007/s13340-025-00864-4
Emi Okamura, Norio Harada, Kana Okuno, Kana Yamamoto, Takaaki Murakami, Yohei Ueda, Daisuke Yabe
{"title":"Insulin edema in slowly progressive type 1 diabetes: improvement following adjustment of insulin therapy.","authors":"Emi Okamura, Norio Harada, Kana Okuno, Kana Yamamoto, Takaaki Murakami, Yohei Ueda, Daisuke Yabe","doi":"10.1007/s13340-025-00864-4","DOIUrl":null,"url":null,"abstract":"<p><p>Insulin edema is an uncommon complication that typically arises soon after initiating insulin therapy, most often in individuals with newly diagnosed diabetes or poorly controlled hyperglycemia. An old report from a single hospital in Africa showed an incidence of 3.5% among 491 insulin-treated individuals. Although the precise pathophysiology remains uncertain, proposed mechanisms include insulin-induced sodium retention, increased vascular permeability, and dysregulation of the renin-angiotensin-aldosterone system. Insulin edema has been described in both type 1 and type 2 diabetes; however, occurrence in slowly progressive type 1 diabetes mellitus (SPIDDM) is exceptionally rare. We report a woman with SPIDDM who developed bilateral lower-leg edema shortly after starting basal-bolus insulin therapy with insulin aspart and insulin degludec. She exhibited no signs of heart failure, liver disease, renal impairment, or allergic reaction to insulin. Cardiac function was normal on echocardiography, and B-type natriuretic peptide levels were within the reference range. She experienced marked edema and an approximately 7-kg weight gain after insulin initiation. Following modification of the insulin regimen and dietary sodium restriction (8 g/day of salt), the edema resolved rapidly within nine days without the use of diuretics. This case illustrates that insulin edema can occur even in individuals with SPIDDM. The observed improvement after insulin regimen adjustment likely reflects the combined influence of glycemic stabilization, fluid-electrolyte balance, and potential formulation-related factors, rather than a direct causal difference between insulin types. Clinicians should recognize this rare yet clinically important complication and adopt an individualized management approach that includes careful glycemic correction and, when appropriate, adjustment of the insulin regimen.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-025-00864-4.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"17 1","pages":"13"},"PeriodicalIF":1.2000,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12748414/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13340-025-00864-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Insulin edema is an uncommon complication that typically arises soon after initiating insulin therapy, most often in individuals with newly diagnosed diabetes or poorly controlled hyperglycemia. An old report from a single hospital in Africa showed an incidence of 3.5% among 491 insulin-treated individuals. Although the precise pathophysiology remains uncertain, proposed mechanisms include insulin-induced sodium retention, increased vascular permeability, and dysregulation of the renin-angiotensin-aldosterone system. Insulin edema has been described in both type 1 and type 2 diabetes; however, occurrence in slowly progressive type 1 diabetes mellitus (SPIDDM) is exceptionally rare. We report a woman with SPIDDM who developed bilateral lower-leg edema shortly after starting basal-bolus insulin therapy with insulin aspart and insulin degludec. She exhibited no signs of heart failure, liver disease, renal impairment, or allergic reaction to insulin. Cardiac function was normal on echocardiography, and B-type natriuretic peptide levels were within the reference range. She experienced marked edema and an approximately 7-kg weight gain after insulin initiation. Following modification of the insulin regimen and dietary sodium restriction (8 g/day of salt), the edema resolved rapidly within nine days without the use of diuretics. This case illustrates that insulin edema can occur even in individuals with SPIDDM. The observed improvement after insulin regimen adjustment likely reflects the combined influence of glycemic stabilization, fluid-electrolyte balance, and potential formulation-related factors, rather than a direct causal difference between insulin types. Clinicians should recognize this rare yet clinically important complication and adopt an individualized management approach that includes careful glycemic correction and, when appropriate, adjustment of the insulin regimen.

Supplementary information: The online version contains supplementary material available at 10.1007/s13340-025-00864-4.

Abstract Image

缓慢进展型1型糖尿病胰岛素水肿:调整胰岛素治疗后的改善
胰岛素水肿是一种罕见的并发症,通常在开始胰岛素治疗后不久出现,最常见于新诊断的糖尿病或控制不良的高血糖患者。一份来自非洲一家医院的旧报告显示,在491名接受胰岛素治疗的患者中,发病率为3.5%。虽然确切的病理生理机制仍不确定,但提出的机制包括胰岛素诱导的钠潴留、血管通透性增加和肾素-血管紧张素-醛固酮系统的失调。胰岛素水肿在1型和2型糖尿病中都有描述;然而,发生在缓慢进展型1型糖尿病(SPIDDM)是非常罕见的。我们报告了一位患有SPIDDM的女性患者,她在开始用天冬氨酸胰岛素和葡糖苷胰岛素进行基础胰岛素治疗后不久出现双侧下肢水肿。她没有表现出心衰、肝病、肾功能损害或胰岛素过敏反应的迹象。超声心动图显示心功能正常,b型利钠肽水平在参考范围内。注射胰岛素后,患者出现明显水肿,体重增加约7公斤。在修改胰岛素治疗方案和限制饮食钠(8 g/天盐)后,在不使用利尿剂的情况下,水肿在9天内迅速消退。本病例说明,即使在SPIDDM患者中也可能发生胰岛素水肿。胰岛素方案调整后观察到的改善可能反映了血糖稳定、液体电解质平衡和潜在配方相关因素的综合影响,而不是胰岛素类型之间的直接因果差异。临床医生应该认识到这种罕见但临床上重要的并发症,并采取个体化的治疗方法,包括仔细的血糖矫正和适当时调整胰岛素治疗方案。补充信息:在线版本包含补充资料,下载地址:10.1007/s13340-025-00864-4。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetology International
Diabetology International ENDOCRINOLOGY & METABOLISM-
CiteScore
3.90
自引率
4.50%
发文量
42
期刊介绍: Diabetology International, the official journal of the Japan Diabetes Society, publishes original research articles about experimental research and clinical studies in diabetes and related areas. The journal also presents editorials, reviews, commentaries, reports of expert committees, and case reports on any aspect of diabetes. Diabetology International welcomes submissions from researchers, clinicians, and health professionals throughout the world who are interested in research, treatment, and care of patients with diabetes. All manuscripts are peer-reviewed to assure that high-quality information in the field of diabetes is made available to readers. Manuscripts are reviewed with due respect for the author''s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editors. The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书